Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™

Cholera Clinical Trial

Official title:

Phase III, Multicenter, Observer-Blinded, Randomized, Active Controlled Trial to Evaluate Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of OCV-S Compared to Shanchol™ in 1 to 40 Years Old Healthy Nepalese Participants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04760236
• Other study ID #: IVI OCV-S
• Status: Completed
• Phase: Phase 3
• Start date: October 6, 2021
• Est. completion date: March 21, 2023

Study information

• Verified date: June 2023
• Source: International Vaccine Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to evaluate immune non-inferiority, safety and lot-to-lot consistency of OCV-S compared to Shanchol™ in 1 to 40 years old healthy Nepalese participants. The investigators hypothesize that the simplified formulation is able to induce non-inferior immunogenicity compared to licensed OCV, Shanchol™.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2530
• Est. completion date: March 21, 2023
• Est. primary completion date: December 22, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 1 Year to 40 Years

Eligibility

Inclusion Criteria:

• Healthy participants 1 to 40 years of age at enrollment
• Participants/Parent(s)/Legally authorized representative (LAR) willing to provide written informed consent to participate study voluntarily
• Participants/Parent(s)/LAR who can be followed up during the study period and can comply with the study requirements

Exclusion Criteria:

• Known history of hypersensitivity reactions to other preventive vaccines
• Severe chronic diseases or medical conditions based on the medical judgment of the investigator. In particular, a participant with a) chronic infection such as tuberculosis, or sequel of poliomyelitis, b) known history of immune function disorders, c) chronic use of systemic steroids (>2 mg/kg/day or >20 mg/day prednisone equivalent for periods exceeding 10 days)/cytotoxic drugs/immunosuppressants within past 6 weeks, d) active malignancy with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease-free for 5 years, e) Congestive heart failure, f) myocardial infarction within the previous 6 months, g) known HIV-infected patients, h) neurological and/or psychiatric disorder, or i) known history of uncontrolled coagulopathy or blood disorders
• Participant who planned to or has received other vaccines from 1 month prior to test vaccination excluding a public health vaccination campaign due to an outbreak
• Participant concomitantly enrolled or scheduled to be enrolled in another trial
• Receipt of blood or blood-derived products in the past 3 months
• Participant who has previously received a cholera vaccine
• Any female participant who is lactating, pregnant or planning for pregnancy during study period
• Participants planning to move from the study area before the end of study period
• Employees or the family members of the OCV-S study sites Temporary Contraindication: Should a participant have one of the conditions/situations listed below, the Investigator will postpone primary or subsequent vaccination until the condition/situation is resolved.
• Febrile illness (axillary temperature = 37.5°C) or moderate or severe acute illness/infection on the day of vaccination or planned vaccination, according to Investigator's judgment.
• Gastrointestinal symptoms including nausea, vomiting, or decreased appetite within 24 hours prior to study initiation.
• Administration of antidiarrheal drugs or antibiotics to treat diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study initiation
• Diarrhea occurring up to 1 week within 6 months prior to study initiation.
• Lactation: Breastfeeding women will not be enrolled. Should a female participant decide to breastfeed during the vaccination period, she will be excluded from further vaccination, but will be followed for safety until the end of the study
• Pregnancy Test is necessary for all married female participants of childbearing age.

Related Conditions & MeSH terms

• Cholera

Intervention

Biological:
• Oral Cholera Vaccine Simplified (OCV-S)
Manufacturer: EuBiologics Co., Ltd. Oral administration
• Shanchol™
Manufacturer: Shantha Biotechnics Oral administration

Locations

Country	Name	City	State
Nepal	Nepalgunj medical college	Banke	City- Nepalgunj
Nepal	Kanti Children's Hospital	Kathmandu	Sukedhara
Nepal	Dhulikhel Hospital	Kavre	Dhulikhel
Nepal	B.P.Koirala Institute of Health Sciences	Rautahat	Dharan

Sponsors (2)

Lead Sponsor	Collaborator
International Vaccine Institute	EuBiologics Co.,Ltd

Country where clinical trial is conducted

Nepal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The equivalence of immunogenicity in 3 lots as measured by seroconversion rates	Proportion of participants showing seroconversion of vibriocidal titers against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of 3 lots of OCV-S in adults	2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™
Other	Vibriocidal antibody responses	Seroconversion rate and GMT of vibriocidal antibody responses 2 weeks after first dose for all ages and for each age stratum	2 weeks after first dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™
Primary	Immune non-inferiority of OCV-S compared to Shanchol™ (i.e., one lot of OCV-S) as measured by seroconversion rates for all ages	Proportion of participants showing seroconversion of vibriocidal titers against Vibrio cholerae O1 Inaba and O1 Ogawa 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ for all ages	2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™
Primary	Vaccine Safety profile	Frequency of solicited adverse events within 7 days post vaccination, unsolicited adverse events within 28 days post vaccination, Serious Adverse Events (SAEs) after each dose during the entire study period in all ages and in each age stratum	As in Description
Secondary	Immune non-inferiority of OCV-S compared to Shanchol™ (i.e., one lot of OCV-S) as measured by GMT for all ages	Geometric Mean Titer (GMT) of vibriocidal antibodies against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ for all ages	2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™
Secondary	Immune non-inferiority of OCV-S compared to Shanchol™ (i.e., one lot of OCV-S) as measured by seroconversion rate in each age stratum	Proportion of participants showing seroconversion against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ in each age stratum	2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™
Secondary	Immune non-inferiority of OCV-S compared to Shanchol™ (i.e., one lot of OCV-S) as measured by GMT in each age stratum	Geometric Mean Titer of vibriocidal antibodies against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ in each age stratum	2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™
Secondary	The equivalence of immunogenicity in 3 lots as measured by GMT	Geometric Mean Titer of vibriocidal antibodies against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of 3 lots of OCV-S in adults	2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™